BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33846569)

  • 1. Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma.
    Fang R; Wang X; Xia Q; Zhao M; Zhang H; Wang X; Ye S; Cheng K; Liang Y; Cheng Y; Gu Y; Rao Q
    Oncogene; 2021 May; 40(18):3303-3317. PubMed ID: 33846569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
    Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
    Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
    Argani P; Antonescu CR; Illei PB; Lui MY; Timmons CF; Newbury R; Reuter VE; Garvin AJ; Perez-Atayde AR; Fletcher JA; Beckwith JB; Bridge JA; Ladanyi M
    Am J Pathol; 2001 Jul; 159(1):179-92. PubMed ID: 11438465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
    Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
    Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
    Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
    Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
    Ladanyi M; Lui MY; Antonescu CR; Krause-Boehm A; Meindl A; Argani P; Healey JH; Ueda T; Yoshikawa H; Meloni-Ehrig A; Sorensen PH; Mertens F; Mandahl N; van den Berghe H; Sciot R; Dal Cin P; Bridge J
    Oncogene; 2001 Jan; 20(1):48-57. PubMed ID: 11244503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
    Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
    J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
    Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
    Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
    Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
    Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
    Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
    Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods.
    Lee HJ; Shin DH; Noh GY; Kim YK; Kim A; Shin N; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
    Oncotarget; 2017 May; 8(19):30756-30765. PubMed ID: 28415646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE).
    Hirobe M; Masumori N; Tanaka T; Kitamura H; Tsukamoto T
    Cancer Biol Ther; 2013 Jun; 14(6):502-10. PubMed ID: 23760492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21.
    Ishiguro N; Yoshida H
    Neoplasia; 2016 Oct; 18(10):626-635. PubMed ID: 27673450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
    Kuroda N; Katto K; Tanaka Y; Yamaguchi T; Inoue K; Ohara M; Mizuno K; Hes O; Michal M; Lee GH
    Med Mol Morphol; 2010 Jun; 43(2):86-90. PubMed ID: 20683695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues.
    Pang LJ; Chang B; Zou H; Qi Y; Jiang JF; Li HA; Hu WH; Chen YZ; Liu CX; Zhang WJ; Li F
    Diagn Mol Pathol; 2008 Dec; 17(4):245-52. PubMed ID: 18382356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
    Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
    Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of a renal cell carcinoma cell line (FU-UR-1) with the reciprocal ASPL-TFE3 fusion transcript.
    Ishiguro M; Iwasaki H; Ohjimi Y; Kaneko Y
    Oncol Rep; 2004 Jun; 11(6):1169-75. PubMed ID: 15138551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
    Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
    Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.